Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Last updated: January 31, 2025
Sponsor: Masonic Cancer Center, University of Minnesota
Overall Status: Active - Recruiting

Phase

N/A

Condition

Histiocytoma

Hypogammaglobulinemia

Sarcoidosis

Treatment

Fludarabine phosphate 30 mg

Fludarabine phosphate 40 mg

MESNA

Clinical Study ID

NCT01652092
2012OC055
MT2012-10C
  • Ages < 50
  • All Genders

Study Summary

This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of immunodeficiency or histiocytic disorder including the following:

  • Severe combined immunodeficiency (SCID - all variants)

  • Second bone marrow transplant (BMT) for SCID (after graft rejection)

  • Omenn's Syndrome

  • Reticular dysgenesis

  • Wiskott-Aldrich syndrome

  • Major histocompatibility complex (MHC) Class II deficiency (bare lymphocyte syndrome)

  • Hyper IgM Syndrome (CD40 Ligand Deficiency)

  • Common variable immunodeficiency (CVID) with severe phenotype

  • Chronic Granulomatous Disease (CGD)

  • Other severe Combined Immune Deficiencies (CID)

  • Hemophagocytic Lymphohistiocytosis (HLH)

  • X-linked Lymphoproliferative Disease (XLP)

  • Chediak-Higashi Syndrome (CHS)

  • Griscelli Syndrome

  • Langerhans Cell Histiocytosis (LCH)

  • Acceptable stem cell sources include:

  • HLA identical or 1 antigen matched sibling donor eligible to donate bone marrow

  • HLA identical or up to a 1 antigen mismatched unrelated BM donor

  • Sibling donor cord blood with acceptable HLA match and cell dose as per current institutional standards

  • Single unrelated umbilical cord blood unit with 0-2 antigen mismatch and minimum cell dose of >5 x 10^7 nucleated cells/kg as per current institutional guidelines

  • Double unrelated umbilical cord blood units that are:

  • up to 2 antigen mismatched to the patient

  • up to 2 antigen mismatched to each other

  • minimum cell dose of at least one single unit must be ≥ 3.5 x 10^7 nucleated cells/kg

  • combined dose of both units must provide a total cell dose of ≥ 5 x 10^7 nucleated cells/kg

  • Age: 0 to 50 years

  • Adequate organ function and performance status.

Exclusion Criteria

  • pregnant or breastfeeding

  • active, uncontrolled infection and/or HIV positive

  • acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on biopsy

Study Design

Total Participants: 30
Treatment Group(s): 9
Primary Treatment: Fludarabine phosphate 30 mg
Phase:
Study Start date:
September 04, 2012
Estimated Completion Date:
December 31, 2026

Study Description

Based on diagnosis and clinical history, a determination of the most appropriate regimen will be made based on the following prep plans:

Arm A: Fully Myeloablative Preparative Regimen, Arm B: Reduced Toxicity Ablative Preparative Regimen, Arm C: Reduced Intensity Conditioning, Arm D: No Preparative Regimen

Connect with a study center

  • Masonic Cancer Center, University of Minnesota

    Minneapolis, Minnesota 55455
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.